本帖最后由 老马 于 2012-1-13 21:20 编辑
. _- z4 P% [0 I! T! w4 k
' U; y% e! J# @1 ?! {" n爱必妥和阿瓦斯丁的比较! G8 K F; u4 ~6 F4 I
" s$ t- J# k! h( C o2 g. |* y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 J; f; H, m# m, U, h
# U& D: i p/ B3 M
0 f S p* X6 {9 q2 S% F: }http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
3 I. R) {, \. l' J==================================================* R$ r% m$ Y( D* s& ^3 O, v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ `$ j: j( `' a+ IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ Y1 a! J( M$ F. S3 K' {( YResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& |' x, A& n2 v6 ?
|